Patent Strategy in Pharmaceutical Industry: Are additional patents valuable?
This book investigates lifecycle management strategies used by pharmaceutical companies attempting to maximize the value of their product portfolio. Such strategies are sometimes referred to by generic drug companies as “evergreening”. The analysis focuses on two of these strategies, namely product...
Kaydedildi:
| Yazar: | |
|---|---|
| Materyal Türü: | Online |
| Dil: | İngilizce |
| Baskı/Yayın Bilgisi: |
Nomos Verlagsgesellschaft mbH & Co. KG
2021
|
| Konular: | |
| Online Erişim: | 29442 |
| Etiketler: |
Etiket eklenmemiş, İlk siz ekleyin!
|
| _version_ | 1869525556089847808 |
|---|---|
| author | Donghi, Monica |
| author_browse | Donghi, Monica |
| author_facet | Donghi, Monica |
| author_sort | Donghi, Monica |
| collection | Directory of Open Access Books |
| description | This book investigates lifecycle management strategies used by pharmaceutical companies attempting to maximize the value of their product portfolio. Such strategies are sometimes referred to by generic drug companies as “evergreening”. The analysis focuses on two of these strategies, namely product improvements and product line extensions. In particular, an evaluation of the patents that follow the basic one and that accompany the development of a drug from research to market is attempted. Two “blockbuster” drugs, Taxotere and Xalatan, were randomly chosen to carry out such analysis. The patent portfolio of the originator companies is outlined and some important patents for each area of research (e.g. formulations, combinations, delivery devices) are shortly described. Patent filing trends for the two drugs, both in regards of the originator and in regards of other competing companies (amongst these also the generics) are schematically shown. |
| format | Online |
| id | doab-20.500.12854ir-55772 |
| institution | Directory of Open Access Books |
| language | eng |
| publishDate | 2021 |
| publishDateRange | 2021 |
| publishDateSort | 2021 |
| publisher | Nomos Verlagsgesellschaft mbH & Co. KG |
| publisherStr | Nomos Verlagsgesellschaft mbH & Co. KG |
| record_format | ojs |
| spelling | doab-20.500.12854ir-557722023-12-20T16:24:46Z Patent Strategy in Pharmaceutical Industry: Are additional patents valuable? Donghi, Monica K1-7720 Markenrecht Urheberrecht / Gewerblicher Rechtsschutz und Medienrecht Gewerblicher Rechtsschutz bic Book Industry Communication::L Law This book investigates lifecycle management strategies used by pharmaceutical companies attempting to maximize the value of their product portfolio. Such strategies are sometimes referred to by generic drug companies as “evergreening”. The analysis focuses on two of these strategies, namely product improvements and product line extensions. In particular, an evaluation of the patents that follow the basic one and that accompany the development of a drug from research to market is attempted. Two “blockbuster” drugs, Taxotere and Xalatan, were randomly chosen to carry out such analysis. The patent portfolio of the originator companies is outlined and some important patents for each area of research (e.g. formulations, combinations, delivery devices) are shortly described. Patent filing trends for the two drugs, both in regards of the originator and in regards of other competing companies (amongst these also the generics) are schematically shown. 2021-02-11T22:19:52Z 2021-02-11T22:19:52Z 2018-11-05 12:58:39 2014 book 29442 9783845251288 https://directory.doabooks.org/handle/20.500.12854/55772 eng Munich Intellectual Property Law Center – MIPLC image/png Attribution 4.0 International https://www.nomos-elibrary.de/10.5771/9783845251288 Nomos Verlagsgesellschaft mbH & Co. KG http://dx.doi.org/10.5771/9783845251288 http://dx.doi.org/10.5771/9783845251288 20c8b06d-3b2b-4af2-acda-fbcfdfea5744 9783845251288 84 open access |
| spellingShingle | K1-7720 Markenrecht Urheberrecht / Gewerblicher Rechtsschutz und Medienrecht Gewerblicher Rechtsschutz bic Book Industry Communication::L Law Donghi, Monica Patent Strategy in Pharmaceutical Industry: Are additional patents valuable? |
| title | Patent Strategy in Pharmaceutical Industry: Are additional patents valuable? |
| title_full | Patent Strategy in Pharmaceutical Industry: Are additional patents valuable? |
| title_fullStr | Patent Strategy in Pharmaceutical Industry: Are additional patents valuable? |
| title_full_unstemmed | Patent Strategy in Pharmaceutical Industry: Are additional patents valuable? |
| title_short | Patent Strategy in Pharmaceutical Industry: Are additional patents valuable? |
| title_sort | patent strategy in pharmaceutical industry are additional patents valuable |
| topic | K1-7720 Markenrecht Urheberrecht / Gewerblicher Rechtsschutz und Medienrecht Gewerblicher Rechtsschutz bic Book Industry Communication::L Law |
| topic_facet | K1-7720 Markenrecht Urheberrecht / Gewerblicher Rechtsschutz und Medienrecht Gewerblicher Rechtsschutz bic Book Industry Communication::L Law |
| url | 29442 |
| work_keys_str_mv | AT donghimonica patentstrategyinpharmaceuticalindustryareadditionalpatentsvaluable |